A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL)
A Phase I Open-Label Dose Escalation Study Of Intravenous INKmune In Patients With Myelodysplastic Syndrome With Excess Blasts (MDS-EB-1/2 - MDS-CMML 1/2) Or Acute Myeloid Leukaemia (AML)
Sponsor: Inmune Bio, Inc.
Terminated
Slow/low Enrollment
Other terminated trials from Inmune Bio, Inc.
More terminations from Inmune Bio, Inc.
Other AML trials with similar outcome
This PHASE1 trial investigates AML and Acute Myeloid Leukemia and is currently terminated or withdrawn. Inmune Bio, Inc. leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Terminated PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE1
▶ Show 1 earlier version
-
Aug 2023 — Apr 2024 [monthly]
Recruiting PHASE1
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Inmune Bio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .